Meanwhile, more than 90% of naive CD4+ T cells sorted from the mammary tumors exhibited CXCR2 (CXCL1 receptor) expression, which was relatively higher than that in non-naive CD4+ T cells (Fig. 4b). This evidence concerns the gene CD4 and breast cancer.